HER-2–targeted drugs, such as trastuzumab (Herceptin), may be useful in a small percentage of cases of lung cancer, the 2% to 3% of non-small cell lung cancers (NSCLCs) that harbor HER2 ...

Two new drug treatments for HER2-positive breast cancer were tested in separate studies. One study involves the drug Tucatinib, and the other involves an antibody-drug called trastuzumab deruxtecan.

More and more, treating HER2-positive breast cancers involves combining an array of drugs. THE FIRST TARGETED TREATMENT for breast cancer that overexpresses the protein HER2 was approved in 1998, ...

New approach to treat drug-resistant HER2--positive breast cancer. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2015 / 04 / 150409133220.htm ...

Enhertu, a breast cancer drug from AstraZeneca and Daiichi Sankyo, is now FDA approved for treating patients whose tumors express low levels of the protein HER2. The decision makes the infused ...

Nov. 4 -- TUESDAY, Nov. 3 (HealthDay News) -- Women with a relatively uncommon type of breast cancer are significantly more likely to face its recurrence and spread, but researchers now say these ...

Novel Anti-HER2 Drugs 'Impressive' in Advanced Biliary Cancer — Response rates reached 41-47% with different approaches in rare disease by Ian Ingram , Managing Editor, MedPage Today June 3 ...

The drug T-Dxd is comprised of a HER2-targeted monoclonal antibody that delivers high concentrations of chemotherapy directly to cancer cells that have HER2 on their surface.

Public Health & Policy > FDA General FDA Panel Backs Novel Anti-HER2 Drug for Breast Cancer — Dissenters cite toxicity, modest benefit. by Charles Bankhead, Senior Editor, MedPage Today, May 24 ...

However, targeted drugs that focus on the HER2 protein are often effective treatment options. If HER2-positive breast cancer is detected and treated early, the chance for a cure is possible. [1] ...